New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
11:51 EDTACT, MYLMylan launches generic actonel tablets, 150 mg
Mylan (MYL) announced that it has launched Risedronate Sodium Tablets USP, 150 mg, the generic version of Warner Chilcott's (ACT) Actonel Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Risedronate Sodium Tablets USP, 150 mg, had U.S. sales of approximately $171.6M for the 12 months ending March 31, according to IMS Health.
News For MYL;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 23, 2015
12:53 EDTACTAnalysts debate potential for competing Salix takeover bid
Subscribe for More Information
07:16 EDTMYLMylan signs exclusive agreement with Gilead to distribute Solvaldi, Harvoni
Subscribe for More Information
February 20, 2015
08:46 EDTACTActavis receives final approval for generic version of Subutex
Actavis announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Reckitt Benckiser's Subutex. Actavis intends to begin shipping its product shortly. Subutex is indicated for the treatment of opioid dependence. For the 12 months ending December 31, 2014, Subutex had total U.S. sales of approximately $108M, according to IMS Health data.
08:07 EDTACTActavis price target raised to $340 from $310 at Argus
Argus increased its price target on Actavis as the firm believes that the company is generating strong growth. Argus is upbeat on the company's acquisition of Allergan and keeps a Buy rating on the shares.
07:08 EDTMYLAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
09:33 EDTACTActavis should be bought on weakness, says Sterne Agee
Subscribe for More Information
07:44 EDTACTActavis to sell 4.2B ordinary shares and $4.2B convertible preferred shares
Subscribe for More Information
07:40 EDTACTActavis price target raised to $352 from $300 at Canaccord
Subscribe for More Information
07:39 EDTACTActavis price target raised to $328 from $310 at Leerink
Subscribe for More Information
07:28 EDTACTActavis files automatic mixed securities shelf
Subscribe for More Information
February 18, 2015
16:46 EDTACTOn The Fly: Closing Wrap
Subscribe for More Information
12:31 EDTACTOn The Fly: Midday Wrap
Subscribe for More Information
09:48 EDTACTActavis Q4 'exceptional,' taking Allergan name 'wise,' says BMO Capital
BMO Capital says Actavis (ACT) is "firing on all cylinders" after reporting "exceptional" Q4 earnings on the strength of the company's North American Generics and International segment. BMO views the decision to adopt the Allergan (AGN) name as "wise" given the Botox maker's strong reputation. The firm keeps an Outperform rating on Actavis.
08:41 EDTMYLThe Medicines Co. says not giving financial guidance due to Hospira suit
Subscribe for More Information
07:50 EDTACTActavis CEO says company gave appropriate guidance to analysts
Actavis (ACT) CEO Saunders said he believes that the company did provide appropriate guidance to analysts ahead of its earnings beat. Saunders sees the Allergan (AGN) deal closing by the end of this quarter or early next quarter. Saunders says tying R&D to a percentage of revenue "makes no sense to me," noting that Actavis will spend about $1.7B on R&D next year. Saunders says will do acquisition if opportunity arises, but not planning for M&A right now. Actavis CEO Brent Saunders is speaking on CNBC.
07:01 EDTACTActavis announces intention to adopt 'Allergan' corporate name
Subscribe for More Information
06:48 EDTACTActavis reports 9 mid-to-late-stage compounds in development
Subscribe for More Information
06:34 EDTACTActavis sees Allergan transaction completed in late Q1 or early Q2
06:33 EDTACTActavis sees FY15 standalone EPS $16.30-$17.30, consensus $16.63
Subscribe for More Information
06:31 EDTACTActavis reports Q4 EPS $3.91, consensus $3.67
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use